Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Narrative Review

Vol. 21 No. 1 (2023)

Does Prolonged Naltrexone Therapy Alter the Rewarding Nature of Exercise, Socialization, and Eating? A Narrative Review

DOI
https://doi.org/10.26443/mjm.v21i1.1058
Submitted
April 26, 2023
Published
2025-01-26

Abstract

Introduction: Naltrexone is an opioid receptor antagonist prescribed for alcohol use disorder and opioid use disorder.  Naltrexone has a high affinity for the mu-opioid receptors, which are the primary binding site of beta-endorphin. Beta-endorphin is an endogenous opioid that functions as the mediator of behavioral reward and reinforcement. Antagonism of the mu-opioid receptors with naltrexone improves certain outcomes in patients with substance use disorder but may alter the positive endogenous reinforcement associated with naturally rewarding and healthy activities including exercising, socializing, and eating.

 

Discussion: In this paper, we review medical literature exploring the potential negative effects of chronic naltrexone therapy on healthy lifestyle modification.

 

Conclusion: Although the data is preliminary, there exists a possibility that naltrexone therapy may adversely impact the endogenous reward system associated with health promoting activities.

 

Relevance: Mortality amongst subjects with substance use disorder has increased to epidemic proportions since fentanyl became widely available. Until relatively recently, behavior modification and Twelve Step programs have been the cornerstones of recovery from substance use disorder. Previous reports have confirmed that exercise, positive social networking, and proper nutrition are important adjunctive therapies in early recovery. The possibility exists that the naturally occurring endorphin mediated reward of these activities may be adversely impacted by naltrexone therapy. Further investigation is warranted to determine whether long-term naltrexone therapy is associated with decreased healthy behaviors and if dose modifications such as low dose or an intermittent dosing scheduling could attenuate this possible unintended consequence of therapy.

References

  1. Sudakin D. Naltrexone: Not Just for Opioids Anymore. Journal of Medical Toxicology. 2016 Mar;12(1):71. https://doi.org/10.1007/s13181-015-0512-x
  2. Trøstheim M, Eikemo M, Haaker J, Frost JJ, Leknes S. Opioid Antagonism in Humans: A Primer on Optimal Dose and Timing for Central Mu-Opioid Receptor Blockade. bioRxiv. 2022 Jan 1; https://doi.org/10.1038/s41386-022-01416-z.
  3. Estave PM, Spodnick MB, Karkhanis AN. KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway. Handb Exp Pharmacol. 2022;271:351–77. https://doi.org/10.1007/164_2020_421.
  4. Pettinati HM, O’Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, et al. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol. 2006 Dec;26(6):610–25. https://doi.org/10.1097/01.jcp.0000245566.52401.20.
  5. Hendershot CS, Wardell JD, Samokhvalov AV, Rehm J. Effects of naltrexone on alcohol self‐administration and craving: meta‐analysis of human laboratory studies. Addict Biol. 2017 Nov;22(6):1515–27. https://doi.org/10.1111/adb.12425.
  6. Roth-Deri I, Green-Sadan T, Yadid G. β-Endorphin and drug-induced reward and reinforcement. Progress in Neurobiology. 2008 Sep;86(1):1–21. https://doi.org/10.1016/j.pneurobio.2008.06.003.
  7. Chiara GD, Alan North R. Neurobiology of opiate abuse. Trends in Pharmacological Sciences. 1992 Jan 1;13:185–93. https://doi.org/10.1016/0165-6147(92)90062-B.
  8. Patterson MS, Spadine MN, Graves Boswell T, Prochnow T, Amo C, Francis AN, et al. Exercise in the Treatment of Addiction: A Systematic Literature Review. Health Educ Behav. 2022 Oct;49(5):801–19. https://doi.org/10.1177/10901981221090155.
  9. Zhang L, Yuan TF. Chapter Ten - Exercise and substance abuse. In: Yau SY, So KF, editors. International Review of Neurobiology [Internet]. Exercise on Brain Health; vol. 147. Academic Press; 2019. p. 269–80. https://doi.org/10.1016/bs.irn.2019.07.007.
  10. Psarianos A, Chryssanthopoulos C, Paparrigopoulos T, Philippou A. The Role of Physical Exercise in Opioid Substitution Therapy: Mechanisms of Sequential Effects. Int J Mol Sci. 2023 Mar 1;24(5):4763. https://doi.org/10.3390/ijms24054763.
  11. Shreffler J, Genova G, Huecker M. Physical activity and exercise interventions for individuals with opioid use disorder: a scoping review. Journal of Addictive Diseases. 2022 Oct 2;40(4):452–62. https://doi.org/10.1080/10550887.2022.2044735.
  12. Siebers M, Biedermann SV, Bindila L, Lutz B, Fuss J. Exercise-induced euphoria and anxiolysis do not depend on endogenous opioids in humans. Psychoneuroendocrinology. 2021 Apr;126:105173. https://doi.org/10.1016/j.psyneuen.2021.105173.
  13. Daniel M, Martin AD, Carter J. Opiate receptor blockade by naltrexone and mood state after acute physical activity. British Journal of Sports Medicine. 1992 Jun 1;26(2):111–5. https://doi.org/10.1136/bjsm.26.2.111.
  14. Knab AM, Lightfoot JT. Does the difference between physically active and couch potato lie in the dopamine system? Int J Biol Sci. 2010;133–50. https://doi.org/10.7150/ijbs.6.133.
  15. Fogelman N, Hwang S, Sinha R, Seo D. Social Support Effects on Neural Stress and Alcohol Reward Responses. In: Miczek KA, Sinha R, editors. Neuroscience of Social Stress [Internet]. Cham: Springer International Publishing; 2022 [cited 2023 Apr 5]. p. 461–82. (Current Topics in Behavioral Neurosciences). https://doi.org/10.1007/7854_2021_246.
  16. Bond J, Kaskutas LA, Weisner C. The persistent influence of social networks and alcoholics anonymous on abstinence. J Stud Alcohol. 2003 Jul;64(4):579–88. https://doi.org/10.15288/jsa.2003.64.579.
  17. Kelly JF, Stout RL, Magill M, Tonigan JS. The role of Alcoholics Anonymous in mobilizing adaptive social network changes: A prospective lagged mediational analysis. Drug Alcohol Depend. 2011 Apr 1;114(2–3):119–26. https://doi.org/10.1016/j.drugalcdep.2010.09.009.
  18. Meier IM, van Honk J, Bos PA, Terburg D. A mu-opioid feedback model of human social behavior. Neuroscience & Biobehavioral Reviews. 2021 Feb 1;121:250–8. https://doi.org/10.1016/j.neubiorev.2020.12.013.
  19. Inagaki TK, Hazlett LI, Andreescu C. Opioids and social bonding: Effect of naltrexone on feelings of social connection and ventral striatum activity to close others. J Exp Psychol Gen. 2020 Apr;149(4):732–45. https://doi.org/10.1037/xge0000674.
  20. Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Wang H, et al. Response of the μ-opioid system to social rejection and acceptance. Mol Psychiatry. 2013 Nov;18(11):1211–7. https://doi.org/10.1038/mp.2013.96.
  21. Depue RA, Morrone-Strupinsky JV. A neurobehavioral model of affiliative bonding: Implications for conceptualizing a human trait of affiliation. Behavioral and Brain Sciences. 2005 Jun;28(3):313–50. https://doi.org/10.1017/S0140525X05000063.
  22. Schweiger D, Stemmler G, Burgdorf C, Wacker J. Opioid receptor blockade and warmth-liking: effects on interpersonal trust and frontal asymmetry. Social Cognitive and Affective Neuroscience. 2014 Oct 1;9(10):1608–15. https://doi.org/10.1093/scan/nst152.
  23. Wiss DA. Chapter 2 - The Role of Nutrition in Addiction Recovery: What We Know and What We Don’t. In: Danovitch I, Mooney LJ, editors. The Assessment and Treatment of Addiction [Internet]. Elsevier; 2019. p. 21–42. https://doi.org/10.1016/B978-0-323-54856-4.00002-X.
  24. Biery JR, Williford JH, McMullen EA. Alcohol craving in rehabilitation: assessment of nutrition therapy. J Am Diet Assoc. 1991 Apr;91(4):463–6.
  25. Fialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. Liver Int. 2015 Sep;35(9):2072–8. https://doi.org/10.1111/liv.12798.
  26. Ghaderi A, Banafshe HR, Motmaen M, Rasouli-Azad M, Bahmani F, Asemi Z. Clinical trial of the effects of vitamin D supplementation on psychological symptoms and metabolic profiles in maintenance methadone treatment patients. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):84–9. https://doi.org/10.1016/j.pnpbp.2017.06.016.
  27. Valbrun LP, Zvonarev V. The Opioid System and Food Intake: Use of Opiate Antagonists in Treatment of Binge Eating Disorder and Abnormal Eating Behavior. J Clin Med Res. 2020 Feb;12(2):41–63. https://doi.org/10.14740/jocmr4066.
  28. de Zwaan M, Mitchell JE. Opiate Antagonists and Eating Behavior in Humans: A Review. The Journal of Clinical Pharmacology. 1992;32(12):1060–72. https://doi.org/10.1177/009127009203201202.
  29. Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev. 2002 Oct;26(6):713–28. https://doi.org/10.1016/s0149-7634(02)00041-6.
  30. Meier IM, Eikemo M, Leknes S. The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies. Curr Addict Rep. 2021 Jun 1;8(2):306–18. https://doi.org/10.1007/s40429-021-00366-8.
  31. Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization. Med Sci (Basel). 2018 Sep 21;6(4):82. https://doi.org/10.3390/medsci6040082.
  32. Plank JR, Glover SC, Moloney BD, Hoeh NR, Sundram F, Sumner RL, et al. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder. Trials. 2022 Sep 30;23(1):822. https://doi.org/1

Downloads

Download data is not yet available.